{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:58:12Z","timestamp":1788897492287,"version":"build-2803163510"},"reference-count":13,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"unspecified","delay-in-days":141,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","award":["Lupus Insight Prize"],"award-info":[{"award-number":["Lupus Insight Prize"]}],"id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Gottfried Wilhelm Leibniz award"],"award-info":[{"award-number":["Gottfried Wilhelm Leibniz award"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of CD19 chimeric antigen receptor (CAR) T cell therapy in a patient with refractory lupus nephritis who experienced severe disease flare during immunosuppressive washout, and to assess whether pulse corticosteroid intervention affects CAR T cell therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a single case of a 22-year-old woman with SLE and lupus podocytopathy refractory to multiple therapies including rituximab, belimumab and obinutuzumab. The patient was treated under single-patient IND (#30146) with autologous CD19 CAR T cells (KYV-101). During the preinfusion washout period, she developed severe lupus flare requiring pulse intravenous methylprednisolone. Clinical outcomes, CAR T cell expansion, B cell depletion and laboratory parameters were monitored before and after therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite experiencing severe lupus flare (fever, rash, arthritis, anti-dsDNA elevation, hypocomplementaemia) during washout, pulse methylprednisolone (250\u2009mg intravenous, rapidly tapered) successfully controlled symptoms without compromising subsequent CAR T cell expansion (peak 15.5\u2009cells\/\u00b5L on day 7). The patient achieved sustained clinical remission with SLE Disease Activity Index Score decreasing from 17 prior to leukapheresis to 4 by week 17. At 12 months postinfusion, she remained in drug-free remission with stable kidney function and had returned to full-time work.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case report illustrates that targeted pulse corticosteroids during CAR T cell therapy washout can effectively manage severe lupus flares without impairing therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001742","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:51:20Z","timestamp":1763628680000},"page":"e001742","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis"],"prefix":"10.1136","volume":"12","author":[{"given":"Jonathan M","family":"Gerber","sequence":"first","affiliation":[{"name":"NYU Langone Health, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Dehdashtian","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangnan","family":"Hu","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Gregoire","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Borie","sequence":"additional","affiliation":[{"name":"Kyverna Therapeutics Inc, Emeryville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorva","family":"Bindal","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Geara","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-1118","authenticated-orcid":false,"given":"Roberto","family":"Caricchio","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2025112000503205000_12.2.e001742.1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/art.42375","article-title":"Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population\u2010Based Study Over Four Decades Using the Lupus Midwest Network","volume":"75","author":"Hocao\u01e7lu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025112000503205000_12.2.e001742.2","first-page":"240","article-title":"Lupus: an overview of the disease and management options","volume":"37","author":"Maidhof","year":"2012","journal-title":"P T"},{"key":"2025112000503205000_12.2.e001742.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2025112000503205000_12.2.e001742.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2025112000503205000_12.2.e001742.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025112000503205000_12.2.e001742.6","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1016\/S2665-9913(23)00209-6","article-title":"Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study","volume":"5","author":"Cho","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025112000503205000_12.2.e001742.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.220"},{"key":"2025112000503205000_12.2.e001742.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0"},{"key":"2025112000503205000_12.2.e001742.9","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.984613","article-title":"Severe lupus nephritis in the present days","volume":"2","author":"Moroni","year":"2022","journal-title":"Front Nephrol"},{"key":"2025112000503205000_12.2.e001742.10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"2025112000503205000_12.2.e001742.11","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746010-00002"},{"key":"2025112000503205000_12.2.e001742.12","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2025112000503205000_12.2.e001742.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:51:21Z","timestamp":1763628681000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/lupus-2025-001742"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001742","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}